Drawing from 39 partner organizations, EHVA encompasses expertise in the fields of molecular biology, structural biology, vectorology, adjuvants delivery, immunology, clinical science and biostatics. The alliance is devised to approach the challenges that have hindered the development of a broadly effective vaccine, to date, from all possible angles.
The multidisciplinary-partnership alliance was initiated by Professor Yves Levy of the French Institute of Health (INSERM) and Professor Giuseppe Pantaleo of the Swiss Vaccine Research Institute at the Lausanne University Hospital (CHUV), and INSERM and CHUV jointly coordinate the five year project. The 39 partnering organisations are located in 16 different countries (11 in Europe, 4 in Sub-Saharan Africa and the US) and the alliance includes academic centres of excellence, leading pharmaceutical companies, start-up companies, a non-profit product-development partnership (the International AIDS Vaccine Initiative), and a non-governmental organisation (the European AIDS Treatment Group)
Below is a list of the partnering organisations including Principal Investigators
